IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24

32 projects completed under PLI Scheme for promotion of domestic manufacturing of Critical KSMs/DIs and APIs

Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme

Atul Bioscience received EIR from USFDA for Ambernath facility

The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

Barentz acquires Anshul Life Sciences to strengthen India portfolio

The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Urgent need to redefine pharma companies’ role on several issues of the industry: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date

Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative

Neuland unveils refreshed brand identity

The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress

Briefs: Dr. Reddy's Laboratories and Ami Organics

Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility